Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42771   clinical trials with a EudraCT protocol, of which   7044   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-003118-42
    Sponsor's Protocol Code Number:D419EC00001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-04-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-003118-42
    A.3Full title of the trial
    Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies
    Estudio de fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad y la eficacia preliminar de Durvalumab en monoterapia o Durvalumab en combinación con Tremelimumab en pacientes pediátricos con tumores sólidos avanzados y neoplasias malignas hematológicas
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical study to evaluate the safety, tolerability and early efficacy of the study drug (Durvalumab) alone and a combination of study drugs (Durvalumab and Tremelimumab) in children with advance solid tumours and blood cancer
    Un estudio clínico para evaluar la seguridad, la tolerabilidad y la eficacia temprana del fármaco de estudio (Durvalumab) solo y una combinación de fármacos de estudio (Durvalumab y Tremelimumab) en niños con tumores sólidos avanzados y cáncer en sangre
    A.4.1Sponsor's protocol code numberD419EC00001
    A.5.4Other Identifiers
    Name:INDNumber:141756
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/081/2018
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca AB
    B.5.2Functional name of contact pointInformation Centre
    B.5.3 Address:
    B.5.3.1Street AddressN/A
    B.5.3.2Town/ citySödertälje
    B.5.3.3Post code151 85
    B.5.3.4CountrySweden
    B.5.6E-mailinformation.centre@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDurvalumab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDURVALUMAB
    D.3.9.1CAS number 1428935-60-7
    D.3.9.2Current sponsor codeMEDI4736
    D.3.9.3Other descriptive nameDURVALUMAB
    D.3.9.4EV Substance CodeSUB176342
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTremelimumab
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTREMELIMUMAB
    D.3.9.1CAS number 745013-59-6
    D.3.9.3Other descriptive nameTREMELIMUMAB
    D.3.9.4EV Substance CodeSUB37101
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced Solid Tumors and Hematological Malignancies
    Tumores sólidos avanzados y neoplasias malignas hematológicas
    E.1.1.1Medical condition in easily understood language
    solid tumours or blood cancer
    tumores sólidos o cáncer en sangre
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10065143
    E.1.2Term Malignant solid tumour
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10066481
    E.1.2Term Hematological malignancy
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Dose-finding:
    -To determine the adult equivalent exposure/MTD/recommended Phase II pediatric dose of durvalumab monotherapy and durvalumab in combination with tremelimumab

    -To determine the safety profile of durvalumab monotherapy, or durvalumab in combination with tremelimumab.

    Dose-expansion:
    To determine the preliminary antitumor activity of durvalumab monotherapy and durvalumab in combination with tremelimumab at the recommended dose, using cohort-specific response criteria (eg, Cheson criteria, Wayne criteria, RECIST 1.1, and INRC).
    Determinación de la dosis:
    -Determinar la exposición equivalente en adultos/DMT/dosis pediátrica recomendada para la fase II de durvalumab en monoterapia y durvalumab en combinación con tremelimumab.
    -Determinar el perfil de seguridad de durvalumab en monoterapia, o durvalumab en combinación con tremelimumab.

    Fase de expansión de la dosis:
    -Determinar la actividad antitumoral preliminar de durvalumab en monoterapia y durvalumab en combinación con tremelimumab a la dosis recomendada, utilizando los criterios de respuesta específicos de la cohorte (p. ej., criterios de Cheson, criterios de Wayne, criterios RECIST 1.1, e INRC).
    E.2.2Secondary objectives of the trial
    Dose-finding and dose-expansion:

    -To describe the PK of durvalumab monotherapy and durvalumab and tremelimumab in combination in children and young adults with solid tumors, or hematological malignancies

    -To determine the immunogenicity of durvalumab monotherapy and durvalumab and tremelimumab in combination in children and young adults with solid tumors

    -To determine the immunogenicity of durvalumab monotherapy and durvalumab in combination with tremelimumab in children and young adults with hematological malignancies

    -To measure effects on immune checkpoint inhibition in response to routine immunizations (dose-expansion phase only).

    -To evaluate immune activation and counts of NK-, B- and T-cells
    Fases de búsqueda de dosis y de expansión de la dosis:
    -Describir la FC de durvalumab en monoterapia y durvalumab y tremelimumab en combinación en niños y adultos jóvenes con tumores sólidos, o neoplasias malignas hematológicas.
    -Determinar la inmunogenia de durvalumab en monoterapia y durvalumab y tremelimumab en combinación en niños y adultos jóvenes con tumores sólidos.
    -Determinar la inmunogenia de durvalumab en monoterapia y durvalumab en combinación con tremelimumab en niños y adultos jóvenes con neoplasias malignas hematológicas.
    -Medir los efectos sobre la inhibición de puntos de control inmunitario en respuesta a las inmunizaciones rutinarias (solo fase de expansión de la dosis).
    -Evaluar la activación inmunitaria y los recuentos de células NK, linfocitos B y T
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Patients must have pathologically confirmed relapsed or refractory advanced solid tumour malignancy or haematological malignancies including lymphoma and acute leukaemia. Any number of prior treatment regimens allowed. A select group of first-line patients may be eligible for screening and enrolment. These patients will be enrolled based on investigator assessment as patients for whom no curative standard of care treatment options exist or such therapies are not tolerable.

    • If available, patients must provide a diagnostic tumor sample taken ˂3 years prior to screening for evaluation of PD-L1 status.

    • Lansky play performance scale ≥50 for patients ≥1 and <16 years of age and Karnofsky performance status score ≥50 for patients ≥16 years of age (patients <1 year of age are exempt from this criterion)

    • Patients must have measurable/evaluable disease as defined by methods used in common clinical practice.

    • No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2 antibodies and antibodies of CAR-T or other cell therapies, excluding therapeutic anticancer vaccines. Exposure to other investigational agents may be permitted after discussion with the Sponsor or designee.
    • Los pacientes deben haber confirmado patológicamente la malignidad sólida avanzada recaída o refractaria del tumor. Cualquier número de regímenes de tratamiento previos permitidos. UN grupo selecto de pacientes de primera línea puede ser elegible para el screening y el enrolamiento. Estos pacientes se enrolarán basándose en la evaluación del investigador como pacientes para los que no existen opciones curativas de tratamiento de la atención médica o tales terapias no son tolerables.

    • Si está disponible, los pacientes deben proporcionar una muestra de diagnóstico del tumor tomada ˂ 3 años antes de la investigación para la evaluación del estado PD-L1.

    • Puntación ≥ 50 del funcionamiento del juego de Lansky para los pacientes entre ≥ 1 y < 16 años de edad y la cuenta del estado del funcionamiento de Karnofsky con resultado ≥ 50 para los pacientes ≥ 16 años de edad (los pacientes < 1 año de la edad están exentos de este criterio)

    • Los pacientes deben tener una enfermedad medible como se define por los métodos utilizados en la práctica clínica común.

    • Ninguna exposición anterior a la terapia inmune-mediada incluyendo, pero no limitado a, el otro anti-CTLA-4, anti-PD-1, anti-PD-L1, los anticuerpos antis-PD-L2 y los anticuerpos de CAR-T u otras terapias de la célula, excluyendo vacunas anticáncer terapéuticas. La exposición a otros agentes de investigación puede ser permitida después de la discusión con el Sponsor o el designado.
    E.4Principal exclusion criteria
    • History of allogeneic organ transplantation (exceptions may be allowed for HL, NHL, ALL and AML, after discussion with Sponsor or designee). Patients who have previously received an autologous bone marrow transplant may be eligible

    • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, celiac disease or other serious GI chronic conditions associated with diarrhea, systemic lupus erythematosus, Wegener syndrome; myasthenia gravis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, etc). The following are exceptions to this criterion:
    − Patients with vitiligo or alopecia
    − Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
    − Psoriasis that does not require systemic therapy
    − Patients with celiac disease controlled by diet alone.

    • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, ILD, or psychiatric illness or social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs from IP, or compromise the ability of the patient to give written informed consent.

    • History of primary immunodeficiency.

    • Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV. Patients with a past or resolved HBV infection are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).

    • Any unresolved toxicity NCI CTCAE version 5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia and the laboratory values defined in the inclusion criteria
    − Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis and may be included after consultation with the Study Physician.
    − Patients with toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab (eg, hearing loss, gastrostomy tube) may be included after consultation with the Study Physician.

    • Patients with clinically active brain metastases (known or suspected) or spinal cord compression are excluded, unless these conditions have been previously treated and are considered stable.

    • History of leptomeningeal carcinomatosis, or involvement of any other anatomic area that, in the opinion of the Investigator, may cause significant symptoms if an inflammatory reaction occurs.
    • Historia del trasplante del órgano (las excepciones se pueden permitir para los HL, el NHL, todos y AML, después de la discusión con el Sponsor o el designado). Los pacientes que han recibido previamente un trasplante de médula ósea pueden ser elegibles

    • Trastornos inflamatorios o autoinmunes activos o previos (incluyendo enfermedades inflamatorias intestinales, diverticulitis, enfermedad celíaca u otras afecciones crónicas del IG grave asociadas con diarrea, lupus eritematoso sistémico, síndrome de Wegener; miastenia gravis, enfermedad grave, artritis reumatoide, hipofisitis, uveitis, etc). Las siguientes son excepciones a este criterio:
    − Pacientes con Vitiligo o alopecia
    − Pacientes con hipotiroidismo (por ejemplo, después del síndrome de Hashimoto) estables en el reemplazo hormonal
    − Psoriasis que no requiere terapia sistémica
    − Pacientes con enfermedad celíaca controlada por dieta sola.

    • Enfermedad incontrolada intercurrente , incluyendo pero no limitado a, la infección en curso o activa, la insuficiencia cardíaca congestiva sintomática, la arritmia cardiaca, la EPI, o las enfermedades psiquiátricas o las situaciones sociales que limitarían el cumplimiento de los requisitos del estudio, aumente substancialmente el riesgo de incurrir en AEs de la IP, o comprometa la capacidad del paciente de dar el consentimiento informado por escrito.

    • Historia de la inmunodeficiencia primaria.

    • Infección activa incluyendo tuberculosis, hepatitis B, hepatitis C, o VIH. Los pacientes con una infección pasada o resuelto del HBV son elegibles. Los pacientes positivos para el anticuerpo del virus de la hepatitis C (HCV) son elegibles solamente si la reacción en cadena de polimerasa es negativa para el ácido ribonucleico de HCV (RNA).

    • Cualquier toxicidad sin resolver NCI CTCAE versión 5,0 grado ≥ 2 de la terapia anticáncer previa con excepción de la alopecia, vitiligo, linfopenia y los valores de laboratorio definidos en los criterios de inclusión
    − Los pacientes con neuropatía de grado ≥ 2 se evaluarán caso por caso y se pueden incluir después de consultar con el médico del estudio.
    − Los pacientes con toxicidad que no se espera razonablemente que se agraven con el tratamiento con durvalumab o tremelimumab (por ejemplo, pérdida auditiva, tubo de gastrostomía) pueden incluirse después de consultar con el médico del estudio.

    • Excluyen a los pacientes con las metástasis cerebrales clínico activas (conocidas o sospechosas) o la compresión de la médula espinal, a menos que estas condiciones hayan sido tratadas previamente y se consideren estables.

    • Historia del leptomeningeal carcinomatosis, o implicación de cualquier otro área anatómica que, en la opinión del investigador, pueda causar síntomas significativos si ocurre una reacción inflamatoria.
    E.5 End points
    E.5.1Primary end point(s)
    Dose-finding:
    1. Based on PK parameters (including Cmax, Cmin, AUC, and others), identify the adult equivalent
    exposure/MTD of durvalumab monotherapy and durvalumab in combination with tremelimumab
    among children and young adults from birth to <18 years of age with advanced solid tumors and non-Hodgkin lymphoma, using a q4w dosing schedule.
    2. Identify the safety and tolerability of durvalumab monotherapy and durvalumab in combination with tremelimumab at the adult equivalent exposure/MTD among children and young adults from birth to <18 years of age with advanced solid tumors and non-Hodgkin lymphoma, using a q4w
    dosing schedule. Endpoints include AEs, vital signs, physical examinations, ECGs, and
    laboratory evaluations.

    Dose-expansion:
    3. Objective response rate as determined by the Investigator assessed RECIST 1.1 or alternative
    pre-specified tumor-specific response rates for different scoring systems.
    -Assessment of antitumor activity will be specific to tumor cohort, eg, Investigator assessed RECIST 1.1, Cheson criteria, Wayne criteria, and INRC (other malignancies will be analyzed based on the best response assessed by the Investigator).
    4. Additional efficacy endpoints that will be collected include DoR, BoR, DCR, PFS, APF12,
    and APF18 based on RECIST 1.1, Cheson criteria, Wayne criteria, or INRC assessed by the
    Investigator, and OS, OS12, and OS24 as appropriate to each individual cohort.
    Fase de búsqueda de dosis:
    1.Basándose en los parámetros de FC (incluidos Cmáx., Cmín., ABC y otros), identificar la exposición equivalente en adultos/DTM de durvalumab en monoterapia y durvalumab en combinación con tremelimumab en niños y jóvenes adultos desde el nacimiento hasta <18 años de edad con tumores sólidos avanzados y linfomas no Hodgkin, utilizando una pauta posológica cada 4 semanas.
    2. Identificar la seguridad y la tolerabilidad de durvalumab en monoterapia y durvalumab en combinación con tremelimumab a la exposición equivalente en adultos/DMT entre niños y jóvenes adultos desde el nacimiento hasta <18 años de edad con tumores sólidos avanzados y linfomas no Hodgkin, utilizando una pauta posológica cada
    4 semanas. Los criterios de valoración incluyen AA, constantes vitales, exploraciones físicas, ECG y evaluaciones analíticas.

    Fase de expansión de la dosis:
    3.Tasa de respuesta objetiva determinada por los RECIST 1.1 evaluados por el investigador o tasas de respuesta específicas para tumores preespecificadas alternativas para los diferentes sistemas de puntuación.
    La evaluación de la actividad antitumoral será específica para la cohorte del tumor, p. ej., criterios RECIST 1.1, criterios de Cheson, criterios de Wayne e INRC evaluados por el investigador (otras neoplasias malignas se analizarán basándose en la mejor respuesta evaluada por el investigador).
    4.Los criterios de valoración de la eficacia adicionales que se recogerán incluyen DR, MRO, TCE, SSP, APF12 y APF18 basados en los criterios RECIST 1.1, criterios de Cheson, criterios de Wayne o INRC evaluados por el investigador y la SG, SG12 y SG24 según corresponda para cada cohorte individual.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. From first dose to cycle 12 on dosing days

    2. From baseline to 90 days post-treatment discontinuation (for AEs)

    3. From baseline to progression

    4. From baseline to death/data cut-off for analysis (survival)
    1. De la primera dosis al ciclo 12 en días de dosificación
    2. Desde basal a la discontinuación del post-tratamiento de 90 días (para AEs)
    3. Desde basal a la progresión
    4. Desde basal a la muerte/corte de datos para el análisis (supervivencia)
    E.5.2Secondary end point(s)
    5. Individual durvalumab and tremelimumab concentrations in serum, and PK parameters
    including Cmax, Cmin, AUC.

    6. Number and percentage of patients who develop detectable ADAs.

    7. Individual antibody titer measurements before and after planned routine immunization during treatment and Cycle 4 or follow-up, whichever is earlier.

    8. Flow cytometry for CD4, CD8, B and NK cells, including T-cell activation with Ki67
    5. Concentraciones individuales de durvalumab y tremelimumab en suero y los parámetros FC, incluidos Cmáx., Cmín, ABC y otros parámetros según corresponda.
    6.Número y porcentaje de pacientes que desarrollan AAF detectables.
    7.Títulos de anticuerpos individuales antes y después de las mediciones de inmunización rutinarias programadas durante el tratamiento y el ciclo 4 o el seguimiento, lo que ocurra antes.
    8.Citometría de flujo para CD4, CD8, linfocitos B y células NK, incluida la activación de los linfocitos T con Ki67.
    E.5.2.1Timepoint(s) of evaluation of this end point
    5. From first dose to cycle 12 on dosing days

    6 & 7. Pre- first dose and pre-dose cycle 6 (durvalumab) and cycle 4 (tremelimumab)

    8. From first dose to cycle 2
    5. de la primera dosis al ciclo 12 en días de dosificación
    6 & 7. Pre-primera dosis y ciclo de pre-dosis 6 (durvalumab) y ciclo 4 (tremelimumab)
    8. de la primera dosis al ciclo 2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Dose-finding & Dose-expansion
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA16
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Italy
    Netherlands
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as 'the last visit of the last patient undergoing the study'.
    El final del estudio se define como "la última visita del último paciente que se encuentra en el estudio".
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 228
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) Yes
    F.1.1.3.1Number of subjects for this age range: 3
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 34
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 80
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 111
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Children from birth until 18 years old
    Niños desde el nacimiento hasta los 18 años de edad
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state14
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 155
    F.4.2.2In the whole clinical trial 228
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After the final analysis, AstraZeneca will continue to supply open-label drug to patients
    receiving durvalumab monotherapy or durvalumab + tremelimumab combination therapy up to
    the time that they discontinue the treatment for whatever reason
    Después del análisis final, AstraZeneca continuará suministrando la medicacion a los pacientes que estén recibiendo monoterapia de durvalumab o terapia combinada de durvalumab + tremelimumab hasta el momento que por cualquier razón suspendan el tratamiento
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-05-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-03-29
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA